PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 2, 2026Annals of Pharmacotherapy

Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Evidence across pharmacokinetic, clinical outcome, and regulatory domains remained discordant regarding apixaban 5 mg versus 2.5 mg twice daily for patients with kidney failure on hemodialysis and AF.

Does apixaban 5 mg twice daily compared to 2.5 mg twice daily improve clinical outcomes or alter pharmacokinetics in patients with kidney failure on hemodialysis and atrial fibrillation?

Population

Patients with kidney failure on hemodialysis with AF across included PK studies, observational cohorts, and RCTs

Comparison

Apixaban 5 mg twice daily vs 2.5 mg twice daily

Design

Systematic review

Key result

Apixaban 5 mg versus 2.5 mg twice daily in kidney failure showed no difference in stroke or systemic embolism (SHR 1.01; 95% CI 0.59-1.73) in observational data, while RCTs remain underpowered.

Authors

SYSoon Hye Yang

Discussion

Loading...

Member takes

Overview

Apixaban 5 mg twice daily should not yet be preferred over 2.5 mg in hemodialysis AF; challenges pharmacokinetic-driven dosing and leaves optimal regimen unresolved pending powered RCTs.

Key Points

  • To evaluate pharmacokinetic, clinical, and regulatory evidence comparing apixaban 5 mg versus 2.5 mg twice daily in patients with atrial fibrillation and kidney failure on hemodialysis.
  • Searched PubMed, EMBASE, and the Cochrane Library from inception through June 2026.
  • Synthesized data from pharmacokinetic studies, observational cohorts, randomized controlled trials, network meta-analyses, and regulatory guidelines.
  • Five pharmacokinetic studies (n ≈ 112) showed that 2.5 mg twice daily matched standard therapeutic exposure, whereas 5 mg twice daily led to an approximately 3-fold supratherapeutic exposure.
  • Among three observational studies, two linked 5 mg to lower mortality, while one identified 63% higher bleeding with 5 mg and no difference in stroke or systemic embolism (SHR 1.01; 95% CI, 0.59–1.73) or death (HR 1.03; 95% CI, 0.77–1.38).
  • Two randomized controlled trials (RENAL-AF and AXADIA-AFNET 8) were terminated early and remain underpowered to confirm clinical efficacy or safety differences.

Study Design

Type

Systematic Review

Structured PICO

Does apixaban 5 mg twice daily compared to 2.5 mg twice daily improve clinical outcomes or alter pharmacokinetics in patients with kidney failure on hemodialysis and atrial fibrillation?

P
Population
Patients with kidney failure on hemodialysis and atrial fibrillation evaluated across pharmacokinetic, observational, and randomized studies.
I
Intervention
Apixaban 5 mg twice daily
C
Comparator
Apixaban 2.5 mg twice daily
O
Outcome
Pharmacokinetic levels and clinical outcomes (stroke/systemic embolism, bleeding, mortality)

Main Result

Hazard Ratio: 1.01 (95% CI 0.59–1.73)

The optimal apixaban dose in hemodialysis patients with AF remains unresolved, highlighting the need for individualized dosing rather than defaulting to FDA labels or pharmacokinetic data alone.

Limitations

  • Confounding by indication
  • Competing risk of death
  • Misapplication of dose-reduction criteria
  • RCTs terminated early and remain underpowered
  • Underpowered RCTs

Cite This Study

Soon Hye Yang (2026) conducted a systematic review in Kidney failure on hemodialysis with atrial fibrillation. Apixaban vs. 2.5 mg twice daily was evaluated on Stroke/systemic embolism (SHR 1.01, 95% CI 0.59-1.73). Apixaban 5 mg versus 2.5 mg twice daily in kidney failure showed no difference in stroke or systemic embolism (SHR 1.01; 95% CI 0.59-1.73) in observational data, while RCTs remain underpowered.

synapsesocial.com/papers/6a97e2b1c562ede874ec6f87https://doi.org/10.1177/10600280261479334
View Full Paper
Ask AI
Bookmark
Share